Sabon binciken yana kawo bege ga marasa lafiya na tinnitus

Wani bincike mai zaman kansa daga Jamus ya tabbatar da cewa bimodal neuromodulation na iya rage yawan alamun tinnitus a cikin yanayin asibiti na ainihi.

Kamfanin na'urar likitancin Irish, Neuromod Devices Ltd. (Neuromod), ya yi maraba da sakamakon binciken wani bincike mai zaman kansa da aka yi a Cibiyar Ji ta Jamus (DHZ) a Makarantar Kiwon Lafiya ta Hannover, wanda ya gano cewa 85% na marasa lafiya na tinnitus sun sami raguwa a cikin alamun tinnitus. (dangane da makin Inventory na Tinnitus Handicap [i] a cikin marasa lafiya 20) lokacin amfani da na'urar jiyya na Lenire.

Wannan binciken ya nuna cewa makonni shida zuwa 12 na jiyya ta amfani da Lenire, na'urar neuromodulation na bimodal wanda Neuromod ya haɓaka wanda ke ba da sauti da kuzari na harshe, na iya samun nasarar samun ingantaccen ma'anar asibiti cikin aminci a cikin alamun alamun tinnitus a cikin yanayin asibiti na ainihi.

An gudanar da binciken ne karkashin jagorancin Dr. Thomas Lenarz, Anke Lesinski-Schiedat, da Andreas Buechner daga Sashen Nazarin Otolaryngology a Makarantar Kiwon Lafiya ta Hannover, Jamus.

An buga waɗannan sakamakon kwanan nan a cikin mujallar kimiyya mai daraja sosai, Ƙwararrun Ƙwararru[ii].

Bayanai na ainihi sun yi daidai da sakamakon gwajin gwajin gwaji na Neuromod (TENT-A1), wanda ya haɗa da mahalarta 326. Gwajin TENT-A1, sakamakon wanda aka buga a watan Oktoba 2020[iii], ya nuna cewa kashi 86.2% na mahalarta da suka yarda da magani sun ba da rahoton ci gaba a cikin alamun tinnitus bayan tsawon makonni 12 ta amfani da Lenire.

Nazarin Hannover ya ƙunshi ɗan gajeren lokaci na jiyya (makonni 6-12) kuma ya lura da haɓaka ma'ana (raguwa) a cikin maki THI na maki 10.4, wanda ya zarce bambancin ma'anar asibiti na maki 7. Wannan bayanan na ainihi daga binciken Hannover ya dace da binciken TENT-A1, wanda ya lura da irin wannan cigaba bayan makonni 6 na jiyya kuma ya sami ci gaba na 14.6 maki inganta bayan cikakken 12 makonni na jiyya. Bugu da ƙari, ba a sami rahoton abubuwan da suka shafi jiyya ba.

Lenire yana aiki ta hanyar isar da ƙananan bugun jini zuwa harshe, ta hanyar wani abu na ciki na baka mai suna 'Tonguetip', hade da sautin da aka kunna ta hanyar belun kunne don fitar da canje-canje na dogon lokaci ko neuroplasticity a cikin kwakwalwa don magance tinnitus.

Gwajin asibiti na TENT-A1, wanda ya haɗa da mahalarta 326 a duk faɗin Ireland da Jamus, sun nuna ingancin Lenire wajen inganta alamun tinnitus na mahalarta. 86.2% na mahalarta masu yarda da magani sun ba da rahoton ci gaba a cikin alamun tinnitus bayan lokacin jiyya na makonni 12[iv]. Lokacin da aka biyo bayan watanni 12 bayan jiyya, 80.1% na mahalarta masu yarda da magani sun sami ci gaba a cikin alamun tinnitus.

Nazarin TENT-A1 yana wakiltar ɗayan mafi girma kuma mafi dadewa na gwaji na asibiti da aka taɓa gudanarwa a cikin filin tinnitus kuma shine labarin murfin mujallar Kimiyyar Fassarar Kimiyya a cikin Oktoba 2020.

Neuromod ya ƙware a cikin fasahar neuromodulation marasa ɓarna kuma ya ƙirƙira da haɓaka Lenire, wanda aka yi amfani da shi don kula da marasa lafiya na tinnitus tun 2019.